PuraMed Bioscience was founded in 2006 and is based in Schofield, Wisconsin. The company began trading under the symbol PMBS in May 2008.
PuraMed engages in the research, development and marketing of non-prescription medicinal and healthcare products. The company emphasizes science as a key component for its success. By partnering with world-class researchers and physicians to conduct and publish world-class research on its products, PuraMed believes it will gain acceptance and credibility from consumers and medical professionals at a much faster and greater rate.
For its initial product line, the company uses a unique sublingual (under the tongue) delivery system, taking advantage of the capillary structure under the tongue which is very close to the surface. Sublingual delivery enables fast absorption and action. It also bypasses the liver and digestive system, avoiding the destruction of the active ingredients by these organs. This allows for lower dosage requirements and increased safety.
PuraMed is currently launching its first product, LipiGesic® M for the treatment of migraine headaches, into the U.S. national retail market. This is a very large market, with approximately 50 million sufferers in the U.S. alone. Migraine headaches are considered to be the most expensive brain disorder in the U.S., costing the economy more than $31 billion in 2010.
A multi-site, double-blind placebo-controlled study, conducted by three nationally recognized headache specialists, was published in a top-tier medical journal in July 2011. This study concluded that LipiGesic M is a highly effective and safe first-line abortive treatment for migraine sufferers. When compared to a meta-analysis of the number one selling prescription treatment, the results of the LipiGesic® M study show it offers a number of advantages. In addition to superior pain relief, LipiGesic® M provides relief from the associated symptoms. It also offers a vastly improved safety profile, no known drug interactions, does not require a physician visit or prescription, and it cuts the treatment cost by at least 75%. These are very powerful advantages, especially for a non-prescription treatment.
In addition to LipiGesic® M, the company also intends to launch two other sublingual gel products in its LipiGesic product line. LipiGesic® H is designed to provide rapid relief from tension-type headaches. More than 100 million people suffer from chronic and episodic tension-type headaches in the U.S. LipiGesic PM is designed to provide relief from insomnia and other sleep disorders. There are more 70 million people who suffer from sleep disorders in the U.S. alone.
The LipiGesic product line effectively addresses three large underserved markets. In addition, the company has approximately 20 other unique products in its pipeline, addressing a broad spectrum of self-limiting disease states including acne, rosacea, age spots and canker sores.
The company believes that by improving the efficiency of delivery, it can provide products that offer superior relief versus current treatment while also dramatically increasing safety and cutting treatment costs significantly.
Market Drivers
50 million migraine sufferers
70 million insomnia sufferers
Total economic cost of migraine headaches exceeded $31 Billion in the United States in 2010. Migraine headaches represent the most costly brain disorder in the United States.
By using sublingual (under the tongue) delivery, the medication is able to work much faster than taking pills.
Sublingual delivery also avoids the "first pass" effect, common with the use of pills, whereby the strength of a drug is greatly reduced before it reaches the systemic circulation. Avoiding this "first pass effect" allows for lower dosages.
Company founders have experience that includes placing products in 50,000 stores nationwide through its brokers and representatives. This enables the Company to achieve broad distribution quickly and at low cost.
There are NO serious adverse events associated with LipiGesic® products for migraine, insomnia or tension headaches.
Unique PuraMed Delivery System
Sublingual delivery (meaning under the tongue) is a superior delivery system to pills because the sublingual delivery works much faster and lower dosage is required. The capillaries under the tongue are extremely close to the surface creating very fast absorption and action. Sublingual delivery not only works faster than most other delivery systems but it also avoids the "first pass" effect, common with the use of pills, whereby the strength of a drug is greatly reduced before it reaches the systemic circulation. Avoiding this "first pass effect" allows for lower dosages.
Distribution
Non-prescription products reach U.S. consumers through approximately 80,000 chain and independent drug, food and mass merchandise retailers (including club stores), 116,000 convenience stores, 4,500 specialty nutrition and health stores, as well as via direct marketing through television, radio, catalogues and the Internet. PuraMed plans to market and distribute its products through mainstream chain drug, independent drug, mass merchandiser, food and warehouse stores. Company founders have experience that includes placing products in 50,000 stores nationwide through its brokers and representatives. This background will enable the Company to achieve broad distribution quickly and at better rates.
RECENT HIGHLIGHTS
Distributing product in Walgreens stores across the nation, with additional key retail chains to follow.
News and Developments
PuraMed BioScience announced today that the independent clinical study of their LipiGesic® M migraine product has been accepted for publication by a top ranked medical journal. The clinical study design was a double blind, placebo controlled, multi-site study measuring the effectiveness of LipiGesic® M for the treatment of acute migraines.
PuraMed BioScience announced today that it has entered into an agreement with Double Pump, Inc. designed to enhance marketing efforts and product awareness surrounding the national retail launch of the Company"s products.
Market Opportunity
LipiGesic® M – Migraine
Over 50 million suffer
1 billion + occurrences/yr.
Majority rely on non prescription medications
Current migraine relief products are marginally effective and have significant side effects
No "alternative" competition
Bests "standard" products
Recurring, non-seasonal
Unique delivery platform
LipiGesic® H – Tension
Over 102 million suffer from chronic and episodic tension-type headache
1 billion occurrences/year
Current tension relief products are marginally effective and have significant side effects
No "alternative" competition
Bests "standard" products
Recurring, non-seasonal
Unique delivery platform
LipiGesic® PM -Insomnia
70 million suffer
5 billion occurrences/yr.
Current insomnia products are marginally effective and have significant side effects
No "alternative" competition
Bests "standard" products
Recurring, non-seasonal
Unique delivery platform
PuraMed engages in the research, development and marketing of non-prescription medicinal and healthcare products. The company emphasizes science as a key component for its success. By partnering with world-class researchers and physicians to conduct and publish world-class research on its products, PuraMed believes it will gain acceptance and credibility from consumers and medical professionals at a much faster and greater rate.
For its initial product line, the company uses a unique sublingual (under the tongue) delivery system, taking advantage of the capillary structure under the tongue which is very close to the surface. Sublingual delivery enables fast absorption and action. It also bypasses the liver and digestive system, avoiding the destruction of the active ingredients by these organs. This allows for lower dosage requirements and increased safety.
PuraMed is currently launching its first product, LipiGesic® M for the treatment of migraine headaches, into the U.S. national retail market. This is a very large market, with approximately 50 million sufferers in the U.S. alone. Migraine headaches are considered to be the most expensive brain disorder in the U.S., costing the economy more than $31 billion in 2010.
A multi-site, double-blind placebo-controlled study, conducted by three nationally recognized headache specialists, was published in a top-tier medical journal in July 2011. This study concluded that LipiGesic M is a highly effective and safe first-line abortive treatment for migraine sufferers. When compared to a meta-analysis of the number one selling prescription treatment, the results of the LipiGesic® M study show it offers a number of advantages. In addition to superior pain relief, LipiGesic® M provides relief from the associated symptoms. It also offers a vastly improved safety profile, no known drug interactions, does not require a physician visit or prescription, and it cuts the treatment cost by at least 75%. These are very powerful advantages, especially for a non-prescription treatment.
In addition to LipiGesic® M, the company also intends to launch two other sublingual gel products in its LipiGesic product line. LipiGesic® H is designed to provide rapid relief from tension-type headaches. More than 100 million people suffer from chronic and episodic tension-type headaches in the U.S. LipiGesic PM is designed to provide relief from insomnia and other sleep disorders. There are more 70 million people who suffer from sleep disorders in the U.S. alone.
The LipiGesic product line effectively addresses three large underserved markets. In addition, the company has approximately 20 other unique products in its pipeline, addressing a broad spectrum of self-limiting disease states including acne, rosacea, age spots and canker sores.
The company believes that by improving the efficiency of delivery, it can provide products that offer superior relief versus current treatment while also dramatically increasing safety and cutting treatment costs significantly.
Market Drivers
50 million migraine sufferers
70 million insomnia sufferers
Total economic cost of migraine headaches exceeded $31 Billion in the United States in 2010. Migraine headaches represent the most costly brain disorder in the United States.
By using sublingual (under the tongue) delivery, the medication is able to work much faster than taking pills.
Sublingual delivery also avoids the "first pass" effect, common with the use of pills, whereby the strength of a drug is greatly reduced before it reaches the systemic circulation. Avoiding this "first pass effect" allows for lower dosages.
Company founders have experience that includes placing products in 50,000 stores nationwide through its brokers and representatives. This enables the Company to achieve broad distribution quickly and at low cost.
There are NO serious adverse events associated with LipiGesic® products for migraine, insomnia or tension headaches.
Unique PuraMed Delivery System
Sublingual delivery (meaning under the tongue) is a superior delivery system to pills because the sublingual delivery works much faster and lower dosage is required. The capillaries under the tongue are extremely close to the surface creating very fast absorption and action. Sublingual delivery not only works faster than most other delivery systems but it also avoids the "first pass" effect, common with the use of pills, whereby the strength of a drug is greatly reduced before it reaches the systemic circulation. Avoiding this "first pass effect" allows for lower dosages.
Distribution
Non-prescription products reach U.S. consumers through approximately 80,000 chain and independent drug, food and mass merchandise retailers (including club stores), 116,000 convenience stores, 4,500 specialty nutrition and health stores, as well as via direct marketing through television, radio, catalogues and the Internet. PuraMed plans to market and distribute its products through mainstream chain drug, independent drug, mass merchandiser, food and warehouse stores. Company founders have experience that includes placing products in 50,000 stores nationwide through its brokers and representatives. This background will enable the Company to achieve broad distribution quickly and at better rates.
RECENT HIGHLIGHTS
Distributing product in Walgreens stores across the nation, with additional key retail chains to follow.
News and Developments
PuraMed BioScience announced today that the independent clinical study of their LipiGesic® M migraine product has been accepted for publication by a top ranked medical journal. The clinical study design was a double blind, placebo controlled, multi-site study measuring the effectiveness of LipiGesic® M for the treatment of acute migraines.
PuraMed BioScience announced today that it has entered into an agreement with Double Pump, Inc. designed to enhance marketing efforts and product awareness surrounding the national retail launch of the Company"s products.
Market Opportunity
LipiGesic® M – Migraine
Over 50 million suffer
1 billion + occurrences/yr.
Majority rely on non prescription medications
Current migraine relief products are marginally effective and have significant side effects
No "alternative" competition
Bests "standard" products
Recurring, non-seasonal
Unique delivery platform
LipiGesic® H – Tension
Over 102 million suffer from chronic and episodic tension-type headache
1 billion occurrences/year
Current tension relief products are marginally effective and have significant side effects
No "alternative" competition
Bests "standard" products
Recurring, non-seasonal
Unique delivery platform
LipiGesic® PM -Insomnia
70 million suffer
5 billion occurrences/yr.
Current insomnia products are marginally effective and have significant side effects
No "alternative" competition
Bests "standard" products
Recurring, non-seasonal
Unique delivery platform
